Theracryf Plc · LSE:TCF
Theracryf — Evgen Pharma — Investor Presentation (May 2018)
29 slides from Theracryf's investor presentation, May 2018
Slide 1: Evgen Pharma plc Investor Presentation May 2018
EVGEN PHARMA PLC Investor Presentation May 2018
Slide 2: Disclaimer
Disclaimer This document has been prepared by, and is the sole responsibility of Evgen Pharma plc (the "Company” or “Evgen”) which trades on the AIM market of the London Stock Exchange under ticker EVG. By attending this presentation and/or reviewing the slides, you agree to be bound by the followin
Slide 3: Presentation download
Presentation download: http://evgen.com/investors/shareholder-information/ 3
Slide 4: Company summary
Company summary § Clinical stage drug development company with a new class of pharmaceuticals § Focused on the development of well-tolerated, stable, sulforaphane-based compounds that: Ø inhibit the STAT3 pathway – a target for reducing cancer proliferation and metastases; and Ø activate the Nrf2 pa
Slide 5: Sulforaphane modulates STAT3 and Nrf2 in oncology and neurology
Sulforaphane modulates STAT3 and Nrf2 presenting opportunities in both oncology and neurology Improving outcomes for Improving outcomes for patients with patients becoming resistant neurodegenerative conditions to cancer therapies References: Sulforaphane as a potential protective phytochemical agai
Slide 6: Pipeline
Pipeline § Potential for different formulations to establish more than one product line based on SFX-01 § Completion of Phase I studies in healthy human volunteers means that SFX-01 is Phase II-ready for other indications § Pipeline further supported by a library of novel derivatives of sulforaphane
Slide 7: Growth in sulforaphane publications and academic collaborations
Growth in sulforaphane publications and strong academic collaborations support the scientific fundamentals Peer reviewed scientific publications "sulforaphane" 250 New sulforaphane analogues 200 Acute Lymphoblastic Leukemia Osteoporosis 150 100 Chemical proteomics / MoA Ischaemic stroke ASD 50 Osteo
Slide 8: SFX-01 in ER+ Metastatic Breast Cancer
SFX-01 in Estrogen-Receptor Positive (ER+) Metastatic Breast Cancer 8
Slide 9: Metastatic estrogen-receptor positive (ER+) breast cancer
Metastatic estrogen-receptor positive (ER+) breast cancer § ER+ breast cancer is the most prevalent breast cancer sub-type § Metastatic breast cancer (also known as “Advanced” or “Stage 4”) means that the cancer has spread to other parts of the body § 5-year survival rates are 22%1 § First-line horm
Slide 10: Market landscape in metastatic ER+ breast cancer
Market landscape in metastatic estrogen receptor positive (ER+) breast cancer § Incidence of ER+ metastatic breast cancer is approximately 130,0001 in US and Europe § CDK4/6 inhibitors are now first line treatment, in combination with hormone therapy § Pfizer (Ibrance®/palbociclib), Novartis (Kisqal
Slide 11: SFX-01 unique mechanism of action in metastatic breast cancer
SFX-01 presents a unique mechanism of action in the metastatic breast cancer therapy landscape Estradiol PI3K Aromatase inhibitors mTOR inhibitors AKT Anastrazole, Letrozole, Everolimus Exemestane ER modulators mTOR SFX-01 Tamoxifen, Fulvestrant ER CDK4/6 inhibitors STAT3 Palbociclib, Ribociclib Cyc
Slide 12: SFX-01 targets cancer stem cells, deactivates STAT3, reduces metastases
SFX-01 targets cancer stem cells, deactivates STAT3 and reduces metastases A C B Li et al (2010) were the first to observe that sulforaphane reduces the size and number of primary mammospheres in human breast cancer cells (A); a property of cancer stem cells (CSCs) In ER+ PDX tumours, SFX-01 reduces
Slide 13: Current clinical progress
Current clinical progress § STEM: SFX-01 treatment and evaluation in patients with metastatic breast cancer § A European, multi-centre, Phase II trial on 60 patients evaluating SFX-01 as an adjunct to failing hormone therapy (i.e. the “salvage” setting) § Hormone resistant “all-comers”: tamoxifen, a
Slide 14: Commercial opportunity and monetisation
Commercial opportunity and monetisation § Substantial market opportunity – CDK4/6i sales projected to reach c.$9bn by 2021e1 § License and/or co-develop SFX-01 as second-line therapy to CDK4/6i § Up-front payment potential of c.$50m2 (although some deals e.g. AstraZeneca/Innate up-front of $250m for
Slide 15: SFX-01 in Subarachnoid Haemorrhage
SFX-01 in Subarachnoid Haemorrhage 15
Slide 16: Aneurysmal subarachnoid haemorrhage (aSAH)
Aneurysmal subarachnoid haemorrhage (aSAH) § Defined by bleeding in the outer layers of the brain due to a ruptured brain aneurysm § 40% to 50% die within 30 days and for the survivors c.50% will have long-term cognitive impairment § Delayed cerebral ischaemia (DCI) occurs days after the aSAH, causi
Slide 17: SAH market landscape
SAH market landscape § Annual incidence of c.50,000 in the EU and c.40,000 in US* § Current standard of care, nimodipine, reduces calcium-dependent smooth muscle contraction but its precise mechanism of action in SAH is unknown § Nimodipine side-effects include unusually fast or slow heart beats and
Slide 18: SFX-01 provides neuroprotection via activation of the Nrf2 pathway
SFX-01 provides neuroprotection via the activation of the Nrf2 pathway SFX-01 Improving outcomes for patients with neurodegenerative conditions SFN Oxidative Oxidative stress stress Inflammation and Inflammation Cell death KEAP1 KEAP1 inflammation SFN SFN NRF2 Cytoprotective proteins NRF2 ARE Bindin
Slide 19: In experimental SAH, sulforaphane upregulates Nrf2, reduces apoptosis
In experimental SAH, sulforaphane upregulates Nrf2, reduces apoptosis and ameliorates motor deficits A B “In the SUL [sulforaphane]- treated group, early brain damage such as brain edema, blood–brain barrier (BBB) impairment, cortical apoptosis, and motor deficits was significantly ameliorated compa
Slide 20: Sulforaphane reduces delayed cerebral ischaemia and improves behavioural scores
Furthermore, sulforaphane reduces the delayed cerebral ischaemia and improves behavioural scores A B “SFN [sulforaphane] has a therapeutic benefit in post- SAH, and this may be due to elevated Nrf2-ARE pathway activity and inhibition of SFN SAH SAH+SFN cerebral vascular Basilar arteries proinflammat
Slide 21: Current clinical progress
Current clinical progress § SAS: SFX-01 After Subarachnoid Haemorrhage – a Phase II, double-blind, placebo-controlled trial on 90 patients (45 in test and placebo arm respectively) § Administered alongside the calcium channel antagonist, nimodipine § Primary Endpoints: improved blood flow (ultrasoun
Slide 22: Commercial opportunity and monetisation
Commercial opportunity and monetisation § Potential peak sales of $500m+ (c.f. $1.7bn for EG19621) as SAH orphan drug § License and/or co-develop post-Phase IIb (2019) to fund pivotal Phase III Ø Up-front payment potential post-Phase IIb of >$70m2 and post-Phase III of >$150m2 Ø Royalty rates estima
Slide 23: Summary
Summary § Evgen is building a stabilised sulforaphane platform (Sulforadex®) with multiple commercialisation routes § Strong preclinical data and mechanistic evidence for broad utility in oncology and neurodegenerative diseases. Benign and well-tolerated § Lead product, SFX-01, is in two Phase II tr
Slide 24: Appendices
APPENDICES 24
Slide 25: Board of Directors
Board of Directors Barry Clare, Chairman Dr Stephen Franklin, Richard Moulson, CFO Dr Marc d’Abbadie, NED Dr Sue Foden, NED Dr Alan Barge, NED Former main Board CEO Founder of Evgen Former CFO of Investor Director at NED and Chair of the Former CMO of ASLAN member of Boots Pharma and former CEO Inte
Slide 26: Sulforaphane inhibits breast cancer stem cells (publication)
NIH Public Access Published in final edited form as: NIH-PA Author Clin Cancer Res. 2010 May 1; 16(9): 2580–2590. doi:10.1158/1078-0432.CCR-09-2937. Author Manuscript Clin Cancer Res. Author manuscript; available in PMC 2011 May 1. Published in final edited form as: Sulforaphane, a Dietary Component
Slide 27: Metastatic Breast Cancer (poster)
mões1, Denis Alferez1, Rachel Eyre1, Kath Spence1, Angelica Santiago-Gomez1, Iris Tanaka1, Francesca Chemi1, Bertram Kohler1, Andy Sims2, Elisabetta Marangoni3, Julia Gee4, east Cancer David Howat5, Sacha Howell1,6, Robert Clarke1 AXIN2 Figure 4: AXIN2, LEF1 and DKK1 genes in 164 primary tumours ACT
Slide 28: Subarachnoid Haemorrhage
Subarachnoid Heamorrhage 28
Slide 29: Role of the Nrf2-ARE Pathway in Early Brain Injury
The nuclear factor erythroid 2-related factor 2 and anti- subarachnoid hemorrhage (SAH; oxidant-response element (Nrf2-ARE) pathway is a key Treatment of EBI is considered regulator for modulating inflammation and oxidative management of patients surviving Journalwhich damage, of Neuroscience are in